Picture this: Starting January 1, a groundbreaking new law is set to bring significant savings on prescription drugs for millions of Americans, potentially transforming how seniors afford their essential medications. But here's where it gets controversial – could this be a step toward fairer healthcare, or is it just the beginning of government overreach into the pharmaceutical industry? Stick around to explore the details and decide for yourself.
This exciting development stems from a policy that's been in the works since the Biden administration, though it officially takes effect in the New Year. It's embedded in the 2022 Inflation Reduction Act, which empowered Medicare – the federal health insurance program primarily for people 65 and older, or those with certain disabilities – to bargain directly with drug manufacturers over prices for specific medications, as reported by USA Today.
Remarkably, even after the Trump administration stripped away some climate and clean energy incentives in the One Big Beautiful Bill (OBBB) Act this summer, they chose to preserve this crucial provision on Medicare drug negotiations. As a result, older adults will enjoy reduced costs for approximately 10 different medications beginning January 1, 2026.
These include popular treatments like Eliquis (a blood thinner), Enbrel (for autoimmune conditions like rheumatoid arthritis), Entresto (for heart failure), Farxiga (for diabetes and heart issues), Januvia (diabetes management), Jardiance (also for diabetes and cardiovascular health), Imbruvica (cancer treatment), NovoLog (insulin for diabetes), Stelara (for psoriasis and inflammatory conditions), and Xarelto (another blood thinner).
Dive deeper into Legal Updates
For those enrolled in Medicare, this could mean slashing out-of-pocket expenses by more than 50% on average for these prescriptions under their plans, based on an AARP study from early December. Although the analysis focused on standalone Medicare drug plans in just five states, experts believe it reflects the nationwide trend.
To put it simply, at least seven of these ten drugs are expected to drop below $100 per month – a game-changer for anyone on a fixed income. Leigh Purvis, AARP's principal for prescription drug policy, emphasized in a statement how vital any financial relief is amid rising living costs and affordability challenges. She described these reductions as a "substantial, impactful enhancement" in today's expensive world.
Currently, about nine million people in the U.S. rely on these ten medications in 2025. With the new pricing next year, the total savings across the board could reach approximately $1.5 billion, according to projections from the Centers for Medicare & Medicaid Services.
AND THERE'S MORE ON THE HORIZON
Just last month, Medicare announced that discounts for an additional 15 drugs, such as Ozempic and Wegovy (used for diabetes and weight management), will kick in starting January 2027. Furthermore, they'll pick a third set of medications for negotiation early next year, with lower prices available by 2028.
However, Americans should be aware that under the OBBB, certain delays or exclusions might apply to some drugs in negotiations, as noted by KFF.
Medications Getting Discounts in January 2026
The initial batch of 10 drugs confirmed for Medicare recipients as of January 1, 2026, includes:
- Eliquis
- Enbrel
- Entresto
- Farxiga
- Januvia
- Jardiance
- Imbruvica
- NovoLog
- Stelara
- Xarelto
Interestingly, cancer treatments like Keytruda and Opdivo are being excluded, even though they're commonly used by Medicare patients. And this is the part most people miss – why these specific drugs and not others? It raises questions about transparency in the selection process.
TRUMP'S CONTRIBUTIONS
On top of that, President Donald Trump has secured agreements with various pharmaceutical firms to offer even more discounted medications through TrumpRx, his upcoming direct-to-consumer online platform launching soon.
"I personally negotiated with pharmaceutical companies and foreign countries that had been exploiting our nation for decades, achieving cuts in drug and pharmaceutical prices of up to 400, 500, and even 600%," Trump stated recently. He mentioned using tariffs as leverage to push for these reductions.
It's worth noting that discounts of 100% or more would essentially make those drugs free, though that's still unconfirmed. Trump did, however, finalize a most-favored-nation deal with Pfizer earlier this year to provide medications at lower costs.
Suggested Reads
Back in May, the President predicted price drops of as much as "90%." This came after concerns arose that tariffs could drive up costs at major retailers like CVS and Walgreens.
What do you think about all this? Is empowering the government to negotiate drug prices a smart move for public health and affordability, or does it risk stifling innovation in the pharmaceutical world? Could Trump's bold claims about massive savings hold up in reality? Share your opinions, agreements, or disagreements in the comments – let's discuss!
